Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

15 results
Display

Photogem Induces Necrosis in Various Uterine Cervical Cancer Cell Lines by PDT

Bae SM, Huh SW, Park EK, Lee KH, Lee JM, Namkoong S, Han SJ, Kim CK, Kim JK, Kim YW, Ahn WS

  • Cancer Res Treat.
  • 2003 Dec;35(6):549-556.
PURPOSE: In order to elucidate the antitumor effect of photodynamic therapy (PDT), using a derivative of the photosensitizing agent hematoporphyrin (Photogem) and a diode laser, the cell death of uterine...
Speculoscopy as Pap Smear Adjunct

Park CH

  • Cancer Res Treat.
  • 2003 Dec;35(6):541-548.
PURPOSE: Speculoscopy, or magnified chemiluminescent examination (MCE), is a new visual method for the detection of cervical neoplasia. It utilizes low magnification and a special "blue-white" chemiluminescent light. The purpose...
cDNA Microarray Experiment: Design Issues in Early Stage and the Need of Normalization

Kim BS, Lee S, Rha SY, Chung HC

  • Cancer Res Treat.
  • 2003 Dec;35(6):533-540.
PURPOSE: The cDNA microarray has become a useful tool for observing the expression of thousands of genes simultaneously. However, obtaining good quality microarray data is not easy due to the...
The Combined Effects of Amifostine and Interleukin 1 Beta (IL-1beta) on Radiation-induced Gastrointestinal and Hematopoietic Injury

Jang SS, Park WY

  • Cancer Res Treat.
  • 2003 Dec;35(6):528-532.
PURPOSE: The pattern of radioprotection by the combined use of low dose amifostine plus IL-1beta was investigated in mice exposed to an acute whole-body radiation dose of 10 Gy. MATERIALS...
Growth Suppression and Induction of Chemosensitivity in Human Gallbladder Epithelial Carcinoma Cells (GBCE) by Adenovirus-Mediated Transfer of the Wild-type p53 Gene

Kim SB, Kim MH, Lee SK, Kim TW, Suh C, Shin JS, Park JS, Kim ES, Gong G, Lee JS, Kim WK, Kim SH

  • Cancer Res Treat.
  • 2003 Dec;35(6):521-527.
PURPOSE: Mutations in the p53 gene are reported in 50~90% of gallbladder and bile duct cancer, and have been implicated in chemoresistance. We undertook this study to determine whether the...
Correlation between p53 and Rb Protein Expression and Clinicopathologic Features in Hepatocellular Carcinoma

Gu MJ, Choi JH

  • Cancer Res Treat.
  • 2003 Dec;35(6):514-520.
PURPOSE: Hepatocellular carcinomas (HCC) are one of the most common cancers in Korea. The mechanism of HCC development is still unclear, and the aberration of the tumor suppressor genes in...
Combined Cytoreductive Surgery and Early Postoperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Gastric Cancer

Ha KI, Bang HY, Lee JI

  • Cancer Res Treat.
  • 2003 Dec;35(6):507-513.
PURPOSE: Peritoneal seeding is the most common type of metastasis or recurrence and one of the poor prognostic factors in gastric cancer. Moreover, there are as yet no effective treatment...
The Effect of ZD 1839 (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer

Kim YT, Kim C, Sohn JH, Park SY, Park SY, Yu NC, Kim YS, Kim SK, Chang J, Kim KD, Chung KY, Kim JH

  • Cancer Res Treat.
  • 2003 Dec;35(6):502-506.
PURPOSE: The aim of this study was to evaluate the efficacy and the safety of ZD 1839 (Iressa(R)) as a 3rd or 4th line chemotherapy regimen in NSCLC patients who...
The Relation between Histopathologic Findings on Surgical Specimen and Outcomes in Patients with N2 Positive Stage IIIA Non-Small Cell Lung Cancer Receiving Preoperative Concurrent Radiochemotherapy and Surgery

Kim BK, Kim KJ, Ahn YC, Lim DH, Park W, Han J, Park K, Kim KM, Kim J, Shim YM

  • Cancer Res Treat.
  • 2003 Dec;35(6):497-501.
PURPOSE: To evaluate the prognostic implication of histopathologic findings on the surgical specimens of N2 positive stage IIIA non-small cell lung cancer (NSCLC) patients who were treated with preoperative concurrent...
Proteomic Profiling of Human Small Cell Lung Cancer Cell Line NCI-H211

Cho HY, Kim MK, Yoo YD, Ahn MJ, Jang JS

  • Cancer Res Treat.
  • 2003 Dec;35(6):489-496.
PURPOSE: Small cell lung cancer is one of the major causes of death from cancer worldwide. To explore the expressions of global protein in small cell lung cancer cells, a...
Genetic Polymorphism of Epoxide Hydrolase and GSTM1 in Lung Cancer Susceptibility of Korean Population

Hwang JH, Kim KS, Kim YI, Kim EJ, Park KH, Cho GJ, Ju JY, Lim SC, Kim YC, Park KO, Park JT, Ahn SJ

  • Cancer Res Treat.
  • 2003 Dec;35(6):483-488.
PURPOSE: Although 80~90% of patients with lung cancer are smokers, only 11% of smokers develop lung cancer. Genetic susceptibility according to the polymorphism of the epoxide hydrolase (mEPHX) gene and...
Telomerase Activity in Gastric Adenocarcinomas: Frozen Tissues Versus Methacarn-fixed Paraffin-embedded Tissues

Yoo J, Kang SJ, Kang CS

  • Cancer Res Treat.
  • 2003 Dec;35(6):478-482.
PURPOSE: Telomerase is an RNA-dependent DNA polymerase that synthesizes TTAGGG telomeric DNA onto chromosome ends to compensate for sequence loss during DNA replication. It has been detected in 85~90% of...
Effect of Arsenic Trioxide in TRAIL (Tumor Necrosis Factor-related Apoptosis Inducing Ligand)-Mediated Apoptosis in Multiple Myeloma Cell Lines

Byun JH, Hong YS, Cheong HJ, Kim SJ, Lee NS, Won JH, Hong DS, Park HS

  • Cancer Res Treat.
  • 2003 Dec;35(6):472-477.
PURPOSE: The potential therapeutic application of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), in the treatment of multiple myeloma (MM), was recently proposed. However, there have been some problems with...
New Functions for Telomerase

Hahn WC

  • Cancer Res Treat.
  • 2003 Dec;35(6):467-471.
Telomeres are nucleoprotein structures that compose the ends of eukaryotic chromosomes and that regulate chromosome integrity and cell proliferative lifespan. Stabilization of telomere length correlates with cell immortalization, and constitutive...
Arsenic Trioxide, an Old Drug? or a New Drug?

Rhee CH

  • Cancer Res Treat.
  • 2003 Dec;35(6):465-466.
No abstract available.

Go to Top

Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr